SCHEMBL6912965

SCHEMBL6912965

CC(NC(=O)OCc1ccccc1)C(=O)C(N)CS(=O)(=O)O.[Zn]

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.48
CTSL P07711 2/20 0.48
CTSS P25774 2/20 0.48
CTSB P07858 1/20 0.48
ATM Q13315 1/20 0.47
CA2 P00918 3/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA9 Q16790 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
ELANE P08246 1/20 0.45
CA5A P35218 1/20 0.44
CTRB1 P17538 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
PLG P00747 1/20 0.44
TPSAB1 Q15661 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6051919 0.99 CTSK (0.49) CTSKCTSLCTSSCTSBATM
SCHEMBL6912269 0.83 CTSK (0.51) CTSKCTSLCTSSCTSBATM
SCHEMBL6908663 0.82 CTSK (0.52) CTSKCTSLCTSSCTSBATM
Alanine SCHEMBL11300392 0.77 CTSK (0.56) CTSKCTSLCTSSCTSBATM
SCHEMBL591894 0.76 CTSK (0.59) CTSKCTSLCTSSCTSBATM
SCHEMBL2627373 0.76 CTSK (0.59) CTSKCTSLCTSSCTSBATM
SCHEMBL591895 0.76 CTSK (0.59) CTSKCTSLCTSSCTSBATM
SCHEMBL31047722 0.76 KYNU (0.59) CTSKCTSLCTSSCTSBCA2
SCHEMBL26459466 0.76 ALDH1A1 (0.57) CTSKCTSLCTSSCTSBALDH1A1
SCHEMBL241564 0.76 CTSK (0.61) CTSKCTSLCTSSCTSBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762174-B1 BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE DOVETAIL TECHNOLOGIES, INC. 2004-07-13 US disclosed
US-6498150-B2 USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS DOVETAIL TECHNOLOGIES, INC. 2002-12-24 US disclosed
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES INC. 2002-03-21 US disclosed
US-6007819-A Methods of inducing immunity using low molecular weight immune stimulants DOVETAIL TECHNOLOGIES, INC. (US) 1999-12-28 US disclosed
WO-1999042099-A1 LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF DOVETAIL TECHNOLOGIES INC. (US) 1999-08-26 WO disclosed
WO-1997014306-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES, INC. (US) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS ACP1, CD14, HPGDS CTSK 1049/4885CTSL 465/4885CTSS 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.